Cargando…

The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis

BACKGROUND: Thyrotoxic periodic paralysis (TPP) is a life-threatening channelopathy manifesting as recurrent episodes of hypokalemia and muscle weakness in the presence of hyperthyroidism. Recent findings indicate defects of inward rectifying K+ (Kir) channels are associated with some TPP patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaobing, Yao, Sheng, Xiang, Yining, Zhang, Xiaolei, Wu, Xiangbing, Luo, Laimin, Huang, Haihua, Zhu, Min, Wan, Hui, Hong, Daojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371807/
https://www.ncbi.nlm.nih.gov/pubmed/25885757
http://dx.doi.org/10.1186/s12883-015-0290-8
_version_ 1782363101241278464
author Li, Xiaobing
Yao, Sheng
Xiang, Yining
Zhang, Xiaolei
Wu, Xiangbing
Luo, Laimin
Huang, Haihua
Zhu, Min
Wan, Hui
Hong, Daojun
author_facet Li, Xiaobing
Yao, Sheng
Xiang, Yining
Zhang, Xiaolei
Wu, Xiangbing
Luo, Laimin
Huang, Haihua
Zhu, Min
Wan, Hui
Hong, Daojun
author_sort Li, Xiaobing
collection PubMed
description BACKGROUND: Thyrotoxic periodic paralysis (TPP) is a life-threatening channelopathy manifesting as recurrent episodes of hypokalemia and muscle weakness in the presence of hyperthyroidism. Recent findings indicate defects of inward rectifying K+ (Kir) channels are associated with some TPP patients. The associations are not only found in Caucasian population (mainly Brazilian), but also in Singaporean population. However, potential genetic risk factors for mainland Chinese patients, the largest group of TPP cases in the world, have been largely unexplored. METHODS: Samples of DNA from 127 individuals with TPP and 102 hyperthyroidism male controls self-reported as mainland Chinese were collected from 5 clinical centers from Jan 2011 to Jan 2014. The KCNJ2 gene, KCNJ18 gene, as well as loci polymorphisms (rs623011and rs312691) at 17q24.3 were directly sequenced in TPP patients and controls. Clinical data were summarized from TPP participants for genotype/phenotype correlations. RESULTS: 3.1% of TPP cases harbored KCNJ18 gene mutations in mainland Chinese patients. Patients with KCNJ18 mutation had shorter attack duration, higher prevalence of muscle soreness and weakness recurrence than patients without KCNJ18 mutation. The alleles at 17q24.3 (rs623011and rs312691) were more common in patients with TPP than in controls, and therefore were significant risk factors for TPP (odds ratio, 11.94 and 10.57; 95% CI, 5.93-24.05 and 5.48-20.40; P = 1.81 × 10(−14) and 1.07 × 10(−14) respectively). CONCLUSIONS: This study demonstrates that the KCNJ18 variants are only responsible for a small proportion of TPP patients in mainland China. There are significant clinical differences between patients with KCNJ18 mutations and patients without KCNJ18 mutations. In addition, the rs623011and rs312691 loci are significantly associated with TPP patients in mainland China, and highlight the Kir2.1 channel as a causative target in TPP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-015-0290-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4371807
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43718072015-03-25 The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis Li, Xiaobing Yao, Sheng Xiang, Yining Zhang, Xiaolei Wu, Xiangbing Luo, Laimin Huang, Haihua Zhu, Min Wan, Hui Hong, Daojun BMC Neurol Research Article BACKGROUND: Thyrotoxic periodic paralysis (TPP) is a life-threatening channelopathy manifesting as recurrent episodes of hypokalemia and muscle weakness in the presence of hyperthyroidism. Recent findings indicate defects of inward rectifying K+ (Kir) channels are associated with some TPP patients. The associations are not only found in Caucasian population (mainly Brazilian), but also in Singaporean population. However, potential genetic risk factors for mainland Chinese patients, the largest group of TPP cases in the world, have been largely unexplored. METHODS: Samples of DNA from 127 individuals with TPP and 102 hyperthyroidism male controls self-reported as mainland Chinese were collected from 5 clinical centers from Jan 2011 to Jan 2014. The KCNJ2 gene, KCNJ18 gene, as well as loci polymorphisms (rs623011and rs312691) at 17q24.3 were directly sequenced in TPP patients and controls. Clinical data were summarized from TPP participants for genotype/phenotype correlations. RESULTS: 3.1% of TPP cases harbored KCNJ18 gene mutations in mainland Chinese patients. Patients with KCNJ18 mutation had shorter attack duration, higher prevalence of muscle soreness and weakness recurrence than patients without KCNJ18 mutation. The alleles at 17q24.3 (rs623011and rs312691) were more common in patients with TPP than in controls, and therefore were significant risk factors for TPP (odds ratio, 11.94 and 10.57; 95% CI, 5.93-24.05 and 5.48-20.40; P = 1.81 × 10(−14) and 1.07 × 10(−14) respectively). CONCLUSIONS: This study demonstrates that the KCNJ18 variants are only responsible for a small proportion of TPP patients in mainland China. There are significant clinical differences between patients with KCNJ18 mutations and patients without KCNJ18 mutations. In addition, the rs623011and rs312691 loci are significantly associated with TPP patients in mainland China, and highlight the Kir2.1 channel as a causative target in TPP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-015-0290-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-21 /pmc/articles/PMC4371807/ /pubmed/25885757 http://dx.doi.org/10.1186/s12883-015-0290-8 Text en © Li et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Xiaobing
Yao, Sheng
Xiang, Yining
Zhang, Xiaolei
Wu, Xiangbing
Luo, Laimin
Huang, Haihua
Zhu, Min
Wan, Hui
Hong, Daojun
The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis
title The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis
title_full The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis
title_fullStr The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis
title_full_unstemmed The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis
title_short The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis
title_sort clinical and genetic features in a cohort of mainland chinese patients with thyrotoxic periodic paralysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4371807/
https://www.ncbi.nlm.nih.gov/pubmed/25885757
http://dx.doi.org/10.1186/s12883-015-0290-8
work_keys_str_mv AT lixiaobing theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT yaosheng theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT xiangyining theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT zhangxiaolei theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT wuxiangbing theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT luolaimin theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT huanghaihua theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT zhumin theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT wanhui theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT hongdaojun theclinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT lixiaobing clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT yaosheng clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT xiangyining clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT zhangxiaolei clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT wuxiangbing clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT luolaimin clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT huanghaihua clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT zhumin clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT wanhui clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis
AT hongdaojun clinicalandgeneticfeaturesinacohortofmainlandchinesepatientswiththyrotoxicperiodicparalysis